Aytu BioPharma is dedicated to advancing healthcare through a diverse portfolio of prescription therapeutics aimed at improving patient health, particularly in pediatric populations. The company focuses on innovative treatments for Attention Deficit Hyperactivity Disorder (ADHD), allergies, and fluoride deficiency. Their product offerings include central nervous system stimulants like ADZENYS XR-ODT, COTEMPLA XR-ODT, and METADATE CD, which are specifically designed for children and adolescents. Additionally, Aytu provides allergy treatments such as Karbinal ER and fluoride-based supplements like Poly-Vi-Flor and Tri-Vi-Flor, which are essential for addressing common health issues in younger patients.

Aytu BioPharma emphasizes a patient-first approach, supported by their Aytu RxConnect program, which enhances patient access to their therapies. The company is committed to not only developing and commercializing novel therapeutics but also ensuring that these products meet the unmet needs of patients. Their mission extends beyond product development to include a focus on corporate sustainability and ethical governance, reflecting their dedication to making a positive impact on healthcare delivery and patient outcomes. Through strategic partnerships and a commitment to innovation, Aytu aims to enhance the quality of life for patients globally.

United States

Aytu BioPharma (NASDAQ: AYTU) is a dynamic specialty pharmaceutical company with a growing commercial portfolio of prescription medicines addressing complex conditions, with a focus on ADHD and other common conditions. Our evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. As we continue on this trajectory, we continue to evaluate novel therapeutics to in-license or acquire. 

Aytu BioPharma

Company Details